Research Alliance Corp III (RACC) stock
RACCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$10.12+0.00 (0.00%)
Close on Nov 17, 2026Market cap $92.08MP/E –Yield –
Research Alliance Corp III r&d expenses
Research and development expenses are spending on new products and technology.
No r&d expenses figures for Research Alliance Corp III
Research Alliance Corp III has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?